Genprex' GPX-002 reverses hyperglycemia in T2D mouse models; data at ASGCT 2026

Genprex, Inc.

GPX-002 (Pdx1/MafA gene therapy) reversed hyperglycemia in HFD-induced T2D mouse models within 4 weeks post-treatment.
Islets from treated mice showed insulin secretion similar to normal-diet mice; improved beta-cell function and maturation.
Treatment increased mature insulin granules and decreased immature granules in beta cells.
Approach deemed potentially translatable to humans via endoscopic retrograde cholangiopancreatography (ERCP).
Data to be presented at ASGCT Annual Meeting, May 11-15, 2026 in Boston.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.